The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Current treatment and recent progress in gastric cancer
Open accessAbstract
Gastric cancer is not a top‐10 malignancy in the United States but represents one of the most common causes of cancer death worldwide. Biological differences between tumors from Eastern and Western countries add to the complexity of identifying standard‐of‐care therapy based on international trials. Systemic chemotherapy, radiotherapy, surgery, immunotherapy, and targeted therapy all have proven efficacy in gastric adenocarcinoma; therefore, multidisciplinary treatment is paramount to treatment selection. Triplet chemotherapy for resectable gastric cancer is now accepted and could represent a plateau of standard cytotoxic chemotherapy for localized disease. Classification of gastric cancer based on molecular subtypes is providing an opportunity for personalized therapy. Biomarkers, in particular microsatellite instability (MSI), programmed cell death ligand 1 (PD‐L1), human epidermal growth factor receptor 2 (HER2), tumor mutation burden, and Epstein‐Barr virus, are increasingly driving systemic therapy approaches and allowing for the identification of populations most likely to benefit from immunotherapy and targeted therapy. Significant research opportunities remain for the less differentiated histologic subtypes of gastric adenocarcinoma and those without markers of immunotherapy activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,334
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
van Hagen, P., Hulshof, M. C. C. M., van Lanschot, J. J. B., Steyerberg, E. W., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., Richel, D. J., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112088 · Cited by 5,521
Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010187 · Cited by 3,475
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,841
Al-Batran, S.-E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., Kopp, H.-G., Mayer, F., Haag, G. M., Luley, K., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32557-1 · Cited by 2,648
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Japanese gastric cancer treatment guidelines 2014 (ver. 4)
Japanese Gastric Cancer Association (2017) · Gastric Cancer · doi:10.1007/s10120-016-0622-4 · Cited by 2,429
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Ychou, M., Boige, V., Pignon, J.-P., Conroy, T., Bouché, O., Lebreton, G., Ducourtieux, M., Bedenne, L., Fabre, J.-M., Saint-Aubert, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0597 · Cited by 2,086
McGuire, S. (2016) · Advances in Nutrition · doi:10.3945/an.116.012211 · Cited by 1,898
Bang, Y.-J., Kim, Y.-W., Yang, H.-K., Chung, H. C., Park, Y.-K., Lee, K. H., Lee, K.-W., Kim, Y. H., Noh, S.-I., Cho, J. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61873-4 · Cited by 1,705
Kim, S. T., Cristescu, R., Bass, A. J., Kim, K.-M., Odegaard, J. I., Kim, K., Liu, X. Q., Sher, X., Jung, H., Lee, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0101-z · Cited by 1,654
Sasako, M., Sakuramoto, S., Katai, H., Kinoshita, T., Furukawa, H., Yamaguchi, T., Nashimoto, A., Fujii, M., Nakajima, T., & Ohashi, Y. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5908 · Cited by 1,434
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333
Shitara, K., Van Cutsem, E., Bang, Y.-J., Fuchs, C., Wyrwicz, L., Lee, K.-W., Kudaba, I., Garrido, M., Chung, H. C., Lee, J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3370 · Cited by 1,141
Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03296 · Cited by 890
Lordick, F., Kang, Y.-K., Chung, H.-C., Salman, P., Oh, S. C., Bodoky, G., Kurteva, G., Volovat, C., Moiseyenko, V. M., Gorbunova, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70102-5 · Cited by 833
Lee, J., Lim, D. H., Kim, S., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Choi, M. G., Sohn, T. S., Noh, J. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1953 · Cited by 803
Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond
Hansford, S., Kaurah, P., Li-Chang, H., Woo, M., Senz, J., Pinheiro, H., Schrader, K. A., Schaeffer, D. F., Shumansky, K., Zogopoulos, G., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.168 · Cited by 694
Satoh, T., Xu, R.-H., Chung, H. C., Sun, G.-P., Doi, T., Xu, J.-M., Tsuji, A., Omuro, Y., Li, J., Wang, J.-W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6136 · Cited by 624
Hecht, J. R., Bang, Y.-J., Qin, S. K., Chung, H. C., Xu, J. M., Park, J. O., Jeziorski, K., Shparyk, Y., Hoff, P. M., Sobrero, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6598 · Cited by 624
Janjigian, Y. Y., Bendell, J., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Ott, P. A., Peltola, K., Jaeger, D., Evans, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6212 · Cited by 624
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Van Cutsem, E., Bang, Y.-J., Feng-yi, F., Xu, J. M., Lee, K.-W., Jiao, S.-C., Chong, J. L., López-Sanchez, R. I., Price, T., Gladkov, O., et al. (2015) · Gastric Cancer · doi:10.1007/s10120-014-0402-y · Cited by 608
Thuss-Patience, P. C., Shah, M. A., Ohtsu, A., Van Cutsem, E., Ajani, J. A., Castro, H., Mansoor, W., Chung, H. C., Bodoky, G., Shitara, K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30111-0 · Cited by 547
Smyth, E. C., Wotherspoon, A., Peckitt, C., Gonzalez, D., Hulkki-Wilson, S., Eltahir, Z., Fassan, M., Rugge, M., Valeri, N., Okines, A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6762 · Cited by 521
Shitara, K., Doi, T., Dvorkin, M., Mansoor, W., Arkenau, H.-T., Prokharau, A., Alsina, M., Ghidini, M., Faustino, C., Gorbunova, V., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30739-3 · Cited by 511
Bang, Y.-J., Ruiz, E. Y., Van Cutsem, E., Lee, K.-W., Wyrwicz, L., Schenker, M., Alsina, M., Ryu, M.-H., Chung, H.-C., Evesque, L., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy264 · Cited by 501
Tabernero, J., Hoff, P. M., Shen, L., Ohtsu, A., Shah, M. A., Cheng, K., Song, C., Wu, H., Eng-Wong, J., Kim, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30481-9 · Cited by 490
Pietrantonio, F., Miceli, R., Raimondi, A., Kim, Y. W., Kang, W. K., Langley, R. E., Choi, Y. Y., Kim, K.-M., Nankivell, M. G., Morano, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01124 · Cited by 487
Yoshida, K., Kodera, Y., Kochi, M., Ichikawa, W., Kakeji, Y., Sano, T., Nagao, N., Takahashi, M., Takagane, A., Watanabe, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01138 · Cited by 392
Ajani, J. A., Winter, K., Okawara, G. S., Donohue, J. H., Pisters, P. W. T., Crane, C. H., Greskovich, J. F., Anne, P. R., Bradley, J. D., Willett, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4840 · Cited by 385
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
Janjigian, Y. Y., Sanchez-Vega, F., Jonsson, P., Chatila, W. K., Hechtman, J. F., Ku, G. Y., Riches, J. C., Tuvy, Y., Kundra, R., Bouvier, N., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0787 · Cited by 375
Janjigian, Y. Y., Maron, S. B., Chatila, W. K., Millang, B., Chavan, S. S., Alterman, C., Chou, J. F., Segal, M. F., Simmons, M. Z., Momtaz, P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30169-8 · Cited by 362
Yan, T. D., Black, D., Sugarbaker, P. H., Zhu, J., Yonemura, Y., Petrou, G., & Morris, D. L. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9487-4 · Cited by 343
Dutton, S. J., Ferry, D. R., Blazeby, J. M., Abbas, H., Dahle-Smith, A., Mansoor, W., Thompson, J., Harrison, M., Chatterjee, A., Falk, S., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70024-5 · Cited by 324
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
Derks, S., Liao, X., Chiaravalli, A. M., Xu, X., Camargo, M. C., Solcia, E., Sessa, F., Fleitas, T., Freeman, G. J., Rodig, S. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9076 · Cited by 308
Ajani, J. A., Mansfield, P. F., Crane, C. H., Wu, T. T., Lunagomez, S., Lynch, P. M., Janjan, N., Feig, B., Faust, J., Yao, J. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.305 · Cited by 282
Kawazoe, A., Fukuoka, S., Nakamura, Y., Kuboki, Y., Wakabayashi, M., Nomura, S., Mikamoto, Y., Shima, H., Fujishiro, N., Higuchi, T., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30271-0 · Cited by 269
Türeci, O., Sahin, U., Schulze-Bergkamen, H., Zvirbule, Z., Lordick, F., Koeberle, D., Thuss-Patience, P., Ettrich, T., Arnold, D., Bassermann, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz199 · Cited by 248
White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer
Leal, A., van Grieken, N. C. T., Palsgrove, D. N., Phallen, J., Medina, J. E., Hruban, C., Broeckaert, M. A. M., Anagnostou, V., Adleff, V., Bruhm, D. C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14310-3 · Cited by 244
Role of symptoms in diagnosis and outcome of gastric cancer
Maconi, G., Manes, G., & Porro, G. B. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.1149 · Cited by 239
Choi, Y. Y., Kim, H., Shin, S.-J., Kim, H. Y., Lee, J., Yang, H.-K., Kim, W. H., Kim, Y.-W., Kook, M.-C., Park, Y. K., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002803 · Cited by 239
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
Lin, S. J., Gagnon-Bartsch, J. A., Tan, I. B., Earle, S., Ruff, L., Pettinger, K., Ylstra, B., van Grieken, N., Rha, S. Y., Chung, H. C., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-308252 · Cited by 229
Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
Maron, S. B., Chase, L. M., Lomnicki, S., Kochanny, S., Moore, K. L., Joshi, S. S., Landron, S., Johnson, J., Kiedrowski, L. A., Nagy, R. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1704 · Cited by 229
Self-citationBang, Y. J., Giaccone, G., Im, S. A., Oh, D. Y., Bauer, T. M., Nordstrom, J. L., Li, H., Chichili, G. R., Moore, P. A., Hong, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx002 · Cited by 226
Moehler, M., Shitara, K., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2296 · Cited by 208
Makiyama, A., Sukawa, Y., Kashiwada, T., Kawada, J., Hosokawa, A., Horie, Y., Tsuji, A., Moriwaki, T., Tanioka, H., Shinozaki, K., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03077 · Cited by 200
Gastric Cancer Etiology and Management in Asia and the West
Russo, A. E., & Strong, V. E. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-081117-043436 · Cited by 181
Fuchs, C. S., Özgüroğlu, M., Bang, Y.-J., Di Bartolomeo, M., Mandala, M., Ryu, M.-H., Fornaro, L., Olesinski, T., Caglevic, C., Chung, H. C., et al. (2022) · Gastric Cancer · doi:10.1007/s10120-021-01227-z · Cited by 167
Al-Batran, S.-E., Pauligk, C., Homann, N., Hartmann, J. T., Moehler, M., Probst, S., Rethwisch, V., Stoehlmacher-Williams, J., Prasnikar, N., Hollerbach, S., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.09.025 · Cited by 165
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
(2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.016 · Cited by 161
Chon, H. J., Hyung, W. J., Kim, C., Park, S., Kim, J., Park, C. H., Ahn, J. B., Kim, H., Chung, H. C., Rha, S. Y., et al. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001793 · Cited by 157
Ikoma, N., Blum, M. A., Chiang, Y., Estrella, J. S., Roy‐Chowdhuri, S., Fournier, K. F., Mansfield, P., Ajani, J. A., & Badgwell, B. D. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5409-7 · Cited by 137
Self-citationMaron, S. B., Alpert, L., Kwak, H. A., Lomnicki, S., Chase, L. M., Xu, D., O’Day, E., Nagy, R. J., Lanman, R. B., Cecchi, F., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1260 · Cited by 129
Okines, A. F. C., Ashley, S. E., Cunningham, D., Oates, J. R., Turner, A., Webb, J., Saffery, C., Chua, Y. J., & Chau, I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2847 · Cited by 125
Greally, M., Chou, J. F., Chatila, W. K., Margolis, M. L., Capanu, M., Hechtman, J. F., Tuvy, Y., Kundra, R., Daian, F., Ladanyi, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3603 · Cited by 104
Resolving gastric cancer aetiology: an update in genetic predisposition
Lott, P. C., & Carvajal‐Carmona, L. G. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30237-1 · Cited by 102
Meric‐Bernstam, F., Beeram, M., Mayordomo, J. I., Hanna, D. L., Ajani, J. A., Murphy, M. B., Murthy, R. K., Piha-Paul, S. A., Bauer, T. M., Bendell, J. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.2500 · Cited by 86
Al‐Batran, S., Schüler, M., Zvirbule, Z., Manikhas, G., Lordick, F., Rusyn, A., Vynnyk, Y., Vynnychenko, I. O., Fadeeva, N., Nechaeva, M. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.18_suppl.lba4001 · Cited by 47
Multimodality Therapy of Localized Gastric Adenocarcinoma
Badgwell, B. D. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0139 · Cited by 38
Self-citationIt Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma
Elimova, E. C., Janjigian, Y. Y., Mulcahy, M. F., Catenacci, D. V. T., Blum, M. A., Almhanna, K., Hecht, J. R., & Ajani, J. A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.7276 · Cited by 32
Moehler, M. H., Janjigian, Y. Y., Adenis, A., Aucoin, J.-S., Boku, N., Chau, I., Cleary, J. M., Feeney, K., Franke, F. A., Mendez, G. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.tps192 · Cited by 31
Cited by
Updates on global epidemiology, risk and prognostic factors of gastric cancer
Yang, W.-J., Zhao, H.-P., Yu, Y., Wang, J.-H., Guo, L., Liu, J.-Y., Pu, J., & Lv, J. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i16.2452 · Cited by 513
Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer
Wang, Y., Zheng, L., Shang, W., Yang, Z., Li, T., Liu, F., Shao, W., Lv, L., Chai, L., Qu, L., et al. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-01008-w · Cited by 422
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Tarantino, P., Carmagnani Pestana, R., Corti, C., Modi, S., Bardia, A., Tolaney, S. M., Cortes, J., Soria, J., & Curigliano, G. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21705 · Cited by 385
Yasuda, T., & Wang, Y. A. (2024) · Trends in Cancer · doi:10.1016/j.trecan.2024.03.008 · Cited by 261
Qiu, M.-Z., Wang, C., Wu, Z., Zhao, Q., Zhao, Z., Huang, C.-Y., Wu, W., Yang, L.-Q., Zhou, Z.-W., Zheng, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01622-1 · Cited by 58
Metadata
- Authors
- Joshi, S. S., & Badgwell, B. D.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2021-02-16
- Volume
- 71
- Issue
- 3
- Pages
- 264-279
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W3129551551
- Cited by
- 1,677
- References
- 68
- FWCI
- 179.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.